$6.86
0.010.15%
At Close: -
$6.86
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Orchestra BioMed Hldgs
OBIONASDAQ
Orchestra BioMed Hldgs (NASDAQ:OBIO) Stock, Analyst Ratings, Price Targets, Predictions
Orchestra BioMed Holdings Inc has a consensus price target of $16.33, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from Chardan Capital, Chardan Capital, and Jefferies on June 12, 2024, March 28, 2024, and January 19, 2024. With an average price target of $18 between Chardan Capital, Chardan Capital, and Jefferies, there's an implied 162.39% upside for Orchestra BioMed Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
Jefferies
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Orchestra BioMed Hldgs
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/12/2024 | Buy Now | 191.55% | Chardan Capital | Keay Nakae | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | Buy Now | 191.55% | Chardan Capital | Keay Nakae | $20 → $20 | Maintains | Buy | Get Alert |
| 01/19/2024 | Buy Now | 104.08% | Jefferies | Matthew Taylor | → $14 | Initiates | → Buy | Get Alert |
| 08/11/2023 | Buy Now | 191.55% | Chardan Capital | Keay Nakae | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 191.55% | Chardan Capital | Keay Nakae | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 191.55% | Chardan Capital | Keay Nakae | → $20 | Reiterates | Buy → Buy | Get Alert |
| 02/24/2023 | Buy Now | 118.66% | Piper Sandler | Matt O'Brien | → $15 | Initiates | → Overweight | Get Alert |
| 02/07/2023 | Buy Now | 191.55% | Chardan Capital | Keay Nakae | → $20 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Orchestra BioMed Hldgs (OBIO) stock?
The latest price target for Orchestra BioMed Hldgs (NASDAQ:OBIO) was reported by Chardan Capital on June 12, 2024. The analyst firm set a price target for $20.00 expecting OBIO to rise to within 12 months (a possible 191.55% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Orchestra BioMed Hldgs (OBIO)?
The latest analyst rating for Orchestra BioMed Hldgs (NASDAQ:OBIO) was provided by Chardan Capital, and Orchestra BioMed Hldgs reiterated their buy rating.
When was the last upgrade for Orchestra BioMed Hldgs (OBIO)?
There is no last upgrade for Orchestra BioMed Hldgs
When was the last downgrade for Orchestra BioMed Hldgs (OBIO)?
There is no last downgrade for Orchestra BioMed Hldgs.
When is the next analyst rating going to be posted or updated for Orchestra BioMed Hldgs (OBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orchestra BioMed Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orchestra BioMed Hldgs was filed on June 12, 2024 so you should expect the next rating to be made available sometime around June 12, 2025.
Is the Analyst Rating Orchestra BioMed Hldgs (OBIO) correct?
While ratings are subjective and will change, the latest Orchestra BioMed Hldgs (OBIO) rating was a reiterated with a price target of $20.00 to $20.00. The current price Orchestra BioMed Hldgs (OBIO) is trading at is $6.86, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.